Greenwich LifeSciences, Inc. announced progress in its Phase III clinical trial FLAMINGO-01, which is studying its immunotherapy GLSI-100 to prevent breast cancer recurrences. The European ...

Sign up for CNN’s Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts. It’s a stance ...

Given the uncertain clinical outcomes and financial instability, I maintain a “Sell” rating on GLSI, awaiting more clarity on the FLAMINGO-01 study. GLSI continues to pursue the development ...

The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by French authorities in Q1 2024, which led to site initiation visits and ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Researchers will soon be able to track the travel trajectory of migratory birds who travel thousands of miles from Eurasia and other parts of the world to reach Odisha’s Chilika Lake during winter.

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by French authorities in Q1 2024, which led to site initiation visits and ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...